Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 30, 2026 07:30 ET | Source: InflaRx N.V.

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos

InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)The Company is assessing the most efficient...
June 30, 2026 05:36 ET | Source: Intravacc B.V.

Intravacc Makes Qualified Vero Cell Banks Available to Accelerate Viral Vaccine Development

Intravacc Makes Qualified Vero Cell Banks Available to Accelerate Viral Vaccine Development
June 26, 2026 13:20 ET | Source: Siren Biotechnology, Inc.

Siren Biotechnology Awarded $8M in Non-Dilutive Grant Funding from the California Institute for Regenerative Medicine (CIRM) to Support Clinical Development of SRN-101 in High-Grade Glioma

Siren Biotechnology awarded $8M in grant funding from the California Institute for Regenerative Medicine (CIRM) to support clinical development of SRN-101
May 06, 2026 08:25 ET | Source: InflaRx N.V.

InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases

InflaRx intends to develop izicopan in ANCA-associated vasculitis (AAV), with a secondary goal of establishing rapid proof of concept in additional life-threatening renal diseasesCapital Markets Day...
April 27, 2026 09:30 ET | Source: Siren Biotechnology, Inc.

Siren Biotechnology Publishes Foundational AAV Immuno-Gene Therapy Data and Announces Presentations at ASGCT 2026

Siren Biotechnology Publishes Foundational AAV Immuno-Gene Therapy Data and Announces Presentations at ASGCT 2026
April 13, 2026 07:00 ET | Source: OXB

OXB launches fast-track offering for AAV and lentiviral vector platforms, accelerating viral vector development and manufacture

New expedited service line designed for biotechs with timeline constraints, launched in response to client demandCan accelerate timeline to GMP manufacturing by up to nine months, driven by key...
February 24, 2026 10:00 ET | Source: Siren Biotechnology, Inc.

Siren Biotechnology Receives FDA Fast Track Designation for SRN-101 for the Treatment of Recurrent High-Grade Glioma

Siren Biotechnology Receives FDA Fast Track Designation for SRN-101 for the Treatment of Recurrent High-Grade Glioma
January 28, 2026 12:00 ET | Source: Siren Biotechnology, Inc.

Siren Biotechnology Announces FDA Clearance of First IND, Advancing Company to Clinical Stage

Siren Biotechnology Announces FDA Clearance of First IND, Advancing Company to Clinical Stage
January 27, 2026 07:30 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics

Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Partnership for Cardiac RNA Therapies
December 04, 2025 08:00 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum

Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum